US2016175406A1PendingUtilityA1

Products and methods for delivery of polynucleotides by adeno-associated virus for lysosomal storage disorders

52
Assignee: NATIONWIDE CHILDRENS HOSPITALPriority: Jun 8, 2011Filed: Nov 24, 2015Published: Jun 23, 2016
Est. expiryJun 8, 2031(~4.9 yrs left)· nominal 20-yr term from priority
A61P 3/00C12Y 310/01001A61K 35/761C12N 9/14A61K 38/46A61K 47/26A61K 48/005C12N 2750/14121C12N 7/00C12N 2750/14171C12N 2750/14143C12N 15/86
52
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present invention relates to methods and materials useful for systemically delivering polynucleotides across the blood brain barrier using adeno-associated virus as a vector. For example, the present invention relates to methods and materials useful for systemically delivering α-N-acetylglucosamidinase polynucleotides to the central and peripheral nervous systems, as well as the somatic system. Use of these methods and materials is indicated, for example, for treatment of the lysosomal storage disorder mucopolysaccharidosis IIIB. As another example, the present invention relates to methods and materials useful for systemically delivering N-sulphoglucosamine sulfphohydrolase polynucleotides to the central and peripheral nervous systems, as well as the somatic system. Use of this second type of methods and materials is indicated, for example, for treatment of the lysosomal storage disorder mucopolysaccharidosis IIIA.

Claims

exact text as granted — not AI-modified
1 - 16 . (canceled) 
     
     
         17 . A method of delivering an N-sulphoglucosamine sulphohydrolase polynucleotide to a patient comprising the step of systemically administering a rAAV9 or rh74 comprising a self-complementary genome including the polynucleotide to a patient. 
     
     
         18 .- 26 . (canceled) 
     
     
         27 . A method of treating mucopolysaccharidosis IIIA comprising the step of systemically administering a rAAV9 or rh74 comprising a self-complementary genome including an N-sulphoglucosamine sulphohydrolase polynucleotide to a patient. 
     
     
         28 . The method of  claim 17  or  27  wherein mannitol is administered prior to the administration of the rAAV. 
     
     
         29 . The method of any one of  claim 17 ,  27  or  28  wherein the sequence of the N-sulphoglucosamine sulphohydrolase polynucleotide is set out in SEQ ID NO: 3. 
     
     
         30 . A rAAV9 or rh74 comprising a genome encoding N-sulphoglucosamine sulphohydrolase. 
     
     
         31 . A composition comprising the rAAV9 or rh74 of  claim 30 . 
     
     
         32 . The rAAV9 or rh74 of  claim 30  wherein the sequence of the N-sulphoglucosamine sulphohydrolase polynucleotide is set out in SEQ ID NO: 3. 
     
     
         33 . The composition of  claim 31  wherein the sequence of the N-sulphoglucosamine sulphohydrolase polynucleotide is set out in SEQ ID NO: 3.

Cited by (0)

No later patents cite this yet.

References (0)

No backward citations on record.